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Abstract
Introduction HGFIN, previously identified as nmb, and its
homolog osteoactivin are single transmembrane proteins that
are expressed in differentiated immune cells. These proteins
exhibit properties that could potentiate tumorigenesis or
decrease invasiveness. These seemingly opposing roles of
HGFIN suggest that this protein might be central to
malignancies and might also behave as a tumor suppressor.
Consistent with the reported roles for HGFIN is the fact that this
gene is regulated by p53 through multiple binding sites in the 5'
flanking region, and is expressed in osteoblasts.
Methods This study used siRNA to knock-out HGFIN in non-
tumorigenic breast cells and ectopically expressed HGFIN in
breast cancer cells. In addition, in situ hybridization studies
analyzed primary breast tissues from archived breast surgeries.
Reporter gene assays studied the untranslated exon 1 of
HGFIN.
Results HGFIN expression led to reduced cell growth of breast
cancer cells and reduced migration. At the molecular level,
reporter gene analyses determined the untranslated exon 1 to
be a negative regulator of the upstream enhancing effect.
Ectopic expression of wild-type p53 in breast cancer cells that
expressed endogenous mutant p53 resulted in increased
HGFIN reporter gene activities.
Conclusion As the majority of cancer cells have mutations in
p53, further studies on the relationship between p53 and
HGFIN expression, and its role in tumor genesis and bone
invasion, might uncover novel therapy targets for breast and
other cancers. The results show a central role for p53 in HGFIN
expression, which appears to determine the behavior of the
cancer cells.
Introduction
Hematopoietic growth factor inducible neurokinin-1 type
(HGFIN; also known as nmb) is a single transmembrane pro-
tein located in human chromosome 7 [1,2]. HGFIN shares
sequence similarities with the G-protein, 7-transmembrane
coupled neurokinin-1 (NK1) receptor [1]. This similarity results
in HGFIN being able to interact with the high affinity ligand for
NK1, substance P [1]. The murine homolog of HGFIN, oste-
oactivin, has been reported to upregulate matrix metalloprotei-
nase-3 and -9 in atrophied skeletal muscles from denervation
[3]. Osteoacvtivin is involved in osteoblast development and
function [2,4,5]. The fact that osteoactivin is expressed in dif-
ferentiated osteoblasts is consistent with human HGFIN being
linked to differentiated immune cells [1,6]. HGFIN has been
reported to act as a negative regulator of inflammation [7,8]. A
recent description of a protein with 99% homology to HGFIN,
DC-HIL show that this gene is promotes adhesion in an RGD-
dependent manner [9].
Osteoactivin and HGFIN are widely expressed in normal and
malignant cells [10]. Osteoactivin is expressed in breast can-
cer cells and has been associated with bone invasion, an
aggressive form of the disease [11]. HGFIN  expression is
partly regulated by p53 through multiple sites within the 5'
flanking region [12]. In contrast to its expression in cancer
cells, in non-transformed cells HGFIN expression appears to
be critical in cell cycle quiescence [1,12]. The link between
p53 and the regulation of HGFIN expression leaves the ques-
tion of the role of HGFIN in tumor development open. Pres-
ence of HGFIN confers low metastatic potential in melanoma
cells [2].
This study further investigates the regulation of HGFIN, and
also determines its involvement in breast cancer. Here, we
report on a repressive effect of the non-coding exon 1. We
also report on the cause–effect relationship between defect in
HGFIN and transformation of non-tumorigenic breast cells.Breast Cancer Research    Vol 9 No 5    Metz et al.
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Materials and methods
Reagents and antibodies
RPMI-1640, DMEM, α-MEM, alkaline phosphatase-conju-
gated goat anti-rabbit IgG, neurokinin-A, and anti-Flag were
purchased from Sigma (St Louis, MO, USA). Fetal calf serum
(FCS) and horse serum were purchased from Hyclone Labo-
ratories (Logan, UT, USA).
Cell lines
K562, MCF12A (non-tumorigenic), MCF10 (non-tumori-
genic), DU4475 (carcinoma), HCC70 and T47D (low inva-
sive) were purchased from American Type Culture Collection
(ATCC; Manassas, VA, USA) and cultured according to their
instructions. The highly aggressive cancer cell line MDA-MB-
231 was obtained from Dr Ian Whitehead, New Jersey Medical
School (Newark, NJ, USA), and was originally described by
ATCC. CCL64 has been described previously [13].
Vectors and reporter gene assay
pGL3-basic and the luciferase detection kit were purchased
from Promega (Madison, WI, USA). The β-galactosidase (β-
gal) detection kit and pHyg were purchased from Clontech
(Palo Alto, CA, USA). pFLAG-CMV2-HGFIN and pPMSKH1
(siRNA) were as previously described [1,14]. pCR2.1 was
purchased from Invitrogen (Carlsbad, CA, USA). The p53
expression vectors and mutants were kindly provided by Dr
Yuzuru Shiio (Institute for Systems Biology, Seattle, WA,
USA): pME18S-SN3 wild-type human p53, pME18S-SCX3
contained 143 Val→Ala mutant human p53, and pPME18S
[15]. The vectors are under the SRα promoter. The expression
vectors encode both the N- and C-termini of p53 [15].
Cloning HGFIN-RM/2.0E
The 5' flanking region of HGFIN, HGFIN-RM/2.0 was as pre-
viously reported [12]. The HUGO Gene Nomenclature Com-
mittee has suggested the official symbol of HGFIN as
GPNMB: human transmembrane glycoprotein nonmetastatic
melanoma protein B. A two-step cloning procedure has been
used to add exon 1, with the translational start site omitted,
downstream of HGFIN-RM/2.0. The clone has been desig-
nated HGFIN-RM/2.0E. The first step used PCR with pooled
human gDNA as template and Hot Start Ex Taq Polymerase
(Invitrogen) with the following primers: 5'-ggtgcagggaag-
gaaaaaagac-3' (sense) and 5'-tagagacattccatgctgaa-3' (anti-
sense). The fragment was inserted into pCR2.1 and was
designated HGFIN-RM/2.1. In the next step, we cloned
HGFIN-RM/2.0E with primers that include exon 1 with omis-
sion of the translation start site: 5'-ctcgaggtgcagggaaggaaa-
3' (sense with XhoI linker) and 5'-aagctttccatgctgaattcc-3'
(antisense with HindIII linker). The fragment was first ligated
into pCR 2.1 for sequencing at the Molecular Core Facility,
New Jersey Medical School (Newark, NJ, USA). After the DNA
sequencing verification, the insert was subcloned into pGL3-
basic reporter vector within XhoI/HindIII sites.
Transfection and reporter gene assay
Reporter gene assays were performed as described [16].
Briefly, non-tumorigenic cells at 60–80% confluence were co-
transfected with pGL3-HGFIN-2.0 or -HGFIN-2.0E and pβ-
gal-control (0.2 μg each). Transfections with Effectene (Qia-
gen, Valencia, CA) results in 60–80% efficiency as deter-
mined by labeling for β-gal [16]. Controls were transfected
with pGL3-basic pβ-gal. After 48h, cell extracts were quanti-
tated for luciferase and β-gal using kits from Promega and
Clontech, respectively. The ratios of luciferase/β-gal in cells
transfected with vector alone were normalized to 1. Luciferase
activities were presented per μg of total protein and the levels
normalized with cells transfected with vector alone. Total pro-
tein in cell extracts was quantitated using a protein assay kit
from BioRad (Hercules, CA, USA).
Stable HGFIN knock-out and expression
The method to construct HGFIN-specific siRNA into
pPMSKH1 has been described previously [14]. HGFIN siRNA
was based on NCBI accession number AF322909 spanning
+343/+361: 5'-catttgcggtgaacctgat-3'. Blast analyses using
NCBI database determined no significant homology to any
human gene. The 19 nucleotide sequence (sense) was placed
in tandem with the loop structure followed by the antisense
sequence of the upstream 19 nucleotide sequence compli-
ment, resulting in 64 nucleotides. Control siRNA contained
single nucleotide mutations within the gene-specific insert.
Double-stranded DNA was ligated into pPMSKH1 at a molar
ratio of 1:50 (vector to insert). Digestion with EcoRI and Hin-
dIII confirmed inserts of ~280 bp. Negative clones without
inserts showed bands at ~220 bp. The insert was further ver-
ified by DNA sequencing at the Molecular Resource Facility,
New Jersey Medical School, Newark, NJ. Stimulated (GM-
CSF) bone marrow fibroblasts have been shown to induce
HGFIN and were therefore used to verify the efficiency of
siRNA in HGFIN knock-out [1].
HGFIN knock-out was performed for MCF12A by co-trans-
fecting with pPMSKH1-HGFIN (wild-type or mutant) and
pHyg. Stable transfectants were selected with hygromycin at
5 μg/mL. HGFIN expression was studied by co-transfecting
T47D with pFLAG-HGFIN and pHyg. Stable transfectants
were selected with 150 μg/mL hygromycin. Selected cells
were positive for Flag by western blots with combination of
whole cell and membrane extracts (data not shown). The com-
binations of extracts were necessary as HGFIN is a membrane
molecule [1].
Western blots
Cell membrane extracts were obtained as previously
described [17]. Briefly, cells were incubated with 400 μL of
1× lysis buffer (Promega) for 15 min at room temperature. Cell
lysates were pelleted by centrifugation at 10,000 g for 15 min
at 4°C and the membrane fractions were resuspended in 300
μL of PBS and then vortexed. Whole cells extracts were pre-Available online http://breast-cancer-research.com/content/9/5/R58
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pared by repeated cycles of freeze–thaw. The membrane and
whole cell extracts were combined and then analyzed for total
protein using the BioRad protein assay.
Extracts (10 μg total protein) were electrophoresed on 12%
SDS-PAGE. Proteins were transferred to PVDF membranes
(Perkin Elmer, Wellesley, MA, USA), and then developed with
anti-Flag by overnight incubation at 4°C. After this, membranes
were washed and incubated with horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG (1/2,000) for 1 h at
4°C. HRP was developed with chemiluminescence western
blot detection reagents (Perkin Elmer). The molecular weights
were determined by comparing to Kaleidoscope prestained
standards (BioRad).
Cell migration assay
Cell migration was studied in a transwell system with 8.0 μm
inserts using 24-well plates (Falcon, Lincoln Park, NJ, USA).
Cells (2 × 105) were re-suspended in sera-free media and
then added into the inner chamber to a volume of 500 μL.
Plates were incubated at 37°C with 5% CO2 for 1.5 h. After
this, cells within the inserts were removed with cotton swabs.
The filter along with the cells that migrated were fixed and
stained with methylene blue. The total numbers of migrated
cells were counted with an inverted light microscope (Olym-
pus, Long Island, NY, USA).
Selection of primary breast cancer cells
Breast tissues were obtained at the initial diagnosis of patients
with Stages IIIA or IIIB. At the time of surgery, patients were
not subjected to chemotherapy or radiation. The use of breast
tissues followed the guidelines of the Institutional Review
Board, Newark Campus. Patient 7 was obtained from Cooper-
ative Human Tissue Network, University of Pennsylvania Med-
ical Center (Philadelphia, PA, USA). Variations in the hormone
status of patients are summarized in Table 1. Malignant cells
within the surgical breast tissues were selected as described
previously [18]. The immunohistochemistry analyses were per-
formed with archived samples from the Pathology Department,
University Hospital, New Jersey Medical School.
In situ hybridization for HGFIN mRNA
Slides with surgical breast samples from benign and malignant
subjects were provided blinded by the co-author of this manu-
script (MH). Thus, the status of the patients (benign vs malig-
nant) was not revealed until after the results were obtained and
analyzed. All patients were diagnosed with infiltrating ductal
carcinomas and none with lobular.
In situ hybridization was performed with a cocktail of three
antisense biotinylated oligonucleotides, 18 nucleotides each,
specific for the HGFIN mRNA, as previously described [1,19].
Briefly, the slides were de-waxed and then incubated with 30
μg/mL proteinase K for 1 h at 37°C. Negative control slides
were incubated with 100 μg/ml RNase for 30 min at 37°C.
After this, slides were prehybridized with 200 ng/mL oligonu-
cleotide cocktail, each with biotin conjugated at the 5' ends.
The oligonucleotides were selected from the two ends, and
middle regions of HGFIN cDNA, accession number
AF322909 [1]: 5'-ccacttgatgccgccaaa-3' (+111/+128); 5'-
atggcaccggccaaagcc-3' (+496/+513); 5'-gcctgtggtatgat-
gtgc-3' (+2235/+2252). Sections were then incubated for 1
h at room temperature with 1.25 μg/ml avidin-AP (Boehringer
Mannheim Biochemicals). Control slides were incubated with
a cocktail of sense oligomers. Slides were counterstained with
Harris Modified Hematoxylin (Fisher Scientific, Springfield, NJ,
USA) and then examined microscopically with Olympus AX-70
microscope and a Magnafire digital camera (Olympus) as
described previously [20]. Photomicrographs were imported
into an image analysis program (analySIS, Soft Imaging Sys-
tem, Munster, Germany) and analyzed to count the positive
labelings. Labeling intensities <0.05 were considered nega-
Table 1
Breast cancer study subjects and hormone status.
Subject (patient no. or tissues) Age range (years) ER PR HER2 (IHC) In situ densities (range)
1–3 65–73 - - - <0.2–1.2
19–28 54–60
29–35 36–60
4–7 55–60 + + 1+ 1–1.5
8–10 60–64
11–18 70–82 + + - 0.5–1
36–50 56–65
Benign tissues 35–60 Not performed Not performed Not performed 10
The demographics of patients and their hormonal status are given. The patients are grouped based on hormonal status and are coded with 
assigned numbers. All patients were diagnosed with infiltrating ductal carcinomas. ER, estrogen receptor; PR, progesterone receptor; HER2, c-
erbB-2; IHC, immunohistochemistry.Breast Cancer Research    Vol 9 No 5    Metz et al.
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tive. The densities of labeling from non-tumorigenic cells were
normalized to 10.
Northern analysis
Northern analysis for steady state HGFIN mRNA was per-
formed as described previously [21]. In brief, total RNA (10
μg) were analyzed with HGFIN cDNA probes, labeled with [α-
32P]-dATP, 3,000 Ci/mM, (Dupont/NEN, Boston, MA, USA).
Membranes were stripped and then re-probed with cDNA for
18S rRNA. Probes were randomly labeled with the Prime-IT II
random primer kit (Stratagene, La Jolla, CA, USA). Hybridized
membranes were developed in a phosphoimager cassette
(Molecular Dynamics, Sunnyvale, CA, USA) and then scanned
after 16 h on a PhosphoImager (Molecular Dynamics). cDNA
for 18S rRNA was purchased from ATCC.
Semi-quantitative RT-PCR
Total RNA was extracted from cells and 2 μg was reverse tran-
scribed. cDNA (200 ng) was subjected to PCR for HGFIN
using primers designed from accession number AF322909,
spanning +570/+681: 5'-aaccttttcctcaccaccc-3' (forward)
and 5'-ttcacagaaactctcactgaac-3' (reverse). PCR reactions
were normalized by amplifying the same sample of cDNA with
primers specific for glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH). The primers for GAPDH spanned +212/
+809 (NM_002046): 5'-ccacccatggcaaattccatggca-3' (for-
ward); 5'-tctagacggcaggtcaggtccacc-3' (reverse). PCR was
performed for 35 cycles for HGFIN and 30 cycles for GAPDH
at 94°C for 30 s, 55°C for 30 s and 72°C for 30 s with a final
extension at 72°C for 10 min. PCR reactions (10 μL) were
separated by electrophoresis on 1.0% agarose containing
ethidium bromide. Band sizes were compared with 1 kb DNA
ladder (Invitrogen).
Growth curve
Cells were plated at 100 cells/T25 tissue culture flasks. At
weekly intervals, cells were trypsinized and then counted.
Methylcellulose cultures
Clonogenic assays were performed as described previously
[14]. Briefly, cells were resuspended in 1.2% methylcellulose
containing the respective culture media. Assays were per-
formed with cells seeded at 102/ml in 35 mm suspension
dishes. Colonies with >20 cells were counted after 5-day
incubation at 37°C.
Data analyses
Statistical evaluations of the data were performed with analy-
sis of variance and Tukey-Kramer multiple comparisons test. A
result of p < 0.05 was considered significant.
Results
HGFIN expression in breast cancer cells
HGFIN is partly regulated by p53 through multiple binding
sites within the 5' flanking region [12]. In addition, HGFIN has
been linked to cell differentiation and cycling quiescence [1].
The murine homologue of HGFIN,  osteoactivin, has been
linked to bone invasion of breast cancer cells [11]. This study
further investigated the role of p53 in HGFIN expression and
its involvement in malignancy of breast cancer.
We screened paraffin sections of breast biopsies for HGFIN
mRNA. This was addressed by in situ hybridization with a
cocktail of biotin-conjugated oligonucleotides. We also exam-
ined malignant breast cells from cell lines and primary sources
for HGFIN mRNA. By RT-PCR, we screened two different
non-tumorigenic cells (NT), MCF12A and MCF10, which
resulted in single bands at the predicted sizes for HGFIN at
112 bp (Figure 1a, top row). In contrast a light band was
observed for DU4475 (T) breast cancer cell line (Figure 1a,
top row). RT-PCR with selected primary breast cancer cells
showed a light band for Stage 0 breast cancer patient (P0)
(Figure 1a, lower row, middle lane) and undetectable bands
for breast cancer cells selected from Stage III patients (P1 and
P38) (Figure 1a, lower row). By northern analyses, we ana-
lyzed total RNA from three cell lines; two malignant and one
non-tumorigenic. The intensity of banding for MCF12A was
>100-fold greater than the malignant cell lines, HCC70 and
T47D (Figure 1b).
In situ hybridization for HGFIN mRNA analyzed fifty breast
biopsies from patients at various stages of breast cancer and
benign tissues. Representative labelings showed dense labels
for benign sections (Figure 1c, arrow), but undetectable labe-
ling for malignant tissue (Figure 1d). In total, we observed high
HGFIN expression in non-tumorigenic breast cells, but
reduced expression in malignant breast cancer cells. Table 1
included the hormonal status to show heterogeneity among
samples. Despite these differences, the expression of HGFIN
depends on malignancy vs benign, irrespective of hormonal
status.
Transformation of HGFIN knock-out MCF12A
Malignant cells showed undetectable and reduced expression
of HGFIN (Figure 1), suggesting a malignant phenotype in
cells with reduced HGFIN expression. We therefore investi-
gated whether HGFIN knock-out in non-tumorigenic MCF12A
could confer a transformed phenotype. Knock-out cells were
studied for contact-independent growth in methylcellulose
matrix and in the growth curve. Control cells were untrans-
fected, stably transfected with vector alone (pPMSKH1) or
mutant HGFIN siRNA. Representative dishes for untrans-
fected or vector transfectants showed no colony by day 5 (Fig-
ure 2a). HGFIN mutant siRNA showed similar findings (data
not shown). HGFIN knock-out MCF12A resulted in large col-
onies (Figure 2a, lower panels: 100 × left; 400 × right),
indicating cell transformation. The total number of colonies
with >20 cells were counted and presented as the mean ±
SD, n = 4. The results showed increased numbers of coloniesAvailable online http://breast-cancer-research.com/content/9/5/R58
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for HGFIN siRNA cells compared to untransfected and vector
transfectants (Figure 2b).
Transformation is generally associated with increased cell
growth. We therefore studied the HGFIN knock-out MCF12A
in growth curves using 100 cells/dish. The growth curve for
vector-transfected MCF12A was similar to untransfected cells
(Figure 2c) and mutant HGFIN siRNA transfectants (data not
shown). In contrast, HGFIN knock-out MCF12A showed
increased cell growth (Figure 2c, triangle symbol). The
increases were significant (p < 0.05) as compared to the other
experimental points beginning at week 4.
Reduced clonogenicity in T47D with ectopic HGFIN
As HGFIN knock-out led to increased growth of MCF12A and
loss of contact-dependent growth (Figure 2), we next consid-
ered whether ectopic expression of HGFIN in a low metastatic
cell line could lead to reduced clonogenicity. We stably trans-
fected T47D with pFLAG-HGFIN, and then analyzed growth in
methylcellulose cultures. After 5 days, colonies were detected
for untransfected cells and vector transfectants (Figure 3, top
and lower panels). No colony was observed for HGFIN-
expressing T47D (Figure 3, middle panel). The cells did not
undergo cell death as determined by trypan blue exclusion
(data not shown). We next counted the total number of colo-
nies in cultures plated with 100 cells/dish and observed a sig-
nificant (p < 0.05) decrease in colonies for HGFIN expressing
cells as compared to untransfected T47D and vector trans-
fectants (Figure 3b). In summary, these results show loss of
contact independent growth in T47D cells ectopically
expressed for HGFIN.
Effect of HGFIN on the migration of T47D and MCF12A
As  HGFIN  confers reduced growth rate, and adherent-
dependent growth (Figures 2 and 3), we next determined
whether these observations correlated with cell migration.
Comparisons were made with MCF12A and T47D. MCF12A
was stable for HGFIN knock-out and T47D was stably
expressed with ectopic pFlag-HGFIN. There was a significant
(p < 0.05) increase in HGFIN knock-out MCF12A as com-
pared to untransfected and mutant siRNA transfectants (Fig-
ure 4a, left bars). In contrast, ectopic-expression of HGFIN in
T47D showed significantly (p < 0.05) reduced migration as
compared to untransfected and vector transfectants (Figure
4a, right bars). In summary, HGFIN expression reduced cell
migration of T47D and MCF12A.
Untranslated exon 1 in the activity of HGFIN reporter 
gene
Previous studies showed an inductive role for p53 in the activ-
ity of HGFIN by reporter gene activities [12]. The report was
based on studies with a 2.0 kb fragment upstream of exon 1,
pGL3-HGFIN-RM/2.0. Exon 1 is an untranslated region of
HGFIN (Figure 5a). We examined the role of exon 1 in non-
tumorigenic cells to determine if this region has regulatory
functions. To this end, we used a reporter gene system with
Figure 1
HGFIN expression in breast cells and tissues HGFIN expression in breast cells and tissues. (a) RT-PCR for HGFIN and GAPDH in non-tumorigenic (NT) (MCF10 and MCF12A) and tumorigenic 
(T) (DU4475) breast cells. P1, P10 and P38 are the non-identifier codes for patients. (b) Total RNA was analyzed by northern analyses for HGFIN 
from MCF12A non-tumorigenic cells and tumorigenic cell lines (HCC70 and T47D). Membranes were stripped and re-probed for 18S rRNA. (c) and 
(d) Representative in situ hybridizations for HGFIN from benign breast tissue, n = 25 (c) and malignant cells, n = 50 (d). Arrow shows dense stain-
ing for alkaline phosphatase (blue) in the benign section. The images were acquired with 100×/0.3 NA objectives.Breast Cancer Research    Vol 9 No 5    Metz et al.
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exon 1 (minus the translational start site), pGL3-HGFIN-RM/
2.0E, to study expressions in MCF12A and three breast can-
cer cell lines. The studies were compared with pGL3-HGFIN-
RM/2.0 in which exon 1 was omitted. HGFIN-RM/2.0E
showed a significant (p < 0.05) decrease in luciferase activi-
ties in MCF12A, T47D and HCC70 (Figure 5b). There was no
significant (p > 0.05) difference between the HGFIN-RM/2.0
and -RM/2.0E in the highly metastatic MDA-MB-231. In addi-
tion, luciferase activities were markedly reduced in MDA-MB-
231 as compared to the other cell lines. This difference was
not due to reduced transfection efficiency as co-transfection
with pGal showed β-gal activity similar to the other cell lines
(data not shown).
Computer analyses were performed for consensus transcrip-
tion sites within exon 1 using Genomatix [22]. The output iden-
tified a consensus sequence for p53 in exon 1 (Figure 5a). We
therefore determined whether high levels of wild-type p53
could reverse the repressive effect of exon 1. This question
was addressed with a cell line that expresses low levels of
p53, CCL64 [23]. Cells were co-transfected with pGL3-
HGFIN-RM/2.0 or -RM/2.0E and/or the following: pME18S-
SN3 wild-type p53, pME18S-SCX3 mutant and pPME18S
vector alone. As we previously reported that HGFIN-RM/2.0
was under the control of p53, an increase by wild-type p53
was not a surprise (Figure 5c, left bars). Despite ectopic wild-
type p53, exon 1 still retained its inhibitory properties, although
Figure 2
Transformation of HGFIN knock-out MCF12A Transformation of HGFIN knock-out MCF12A. (a) Representative colonies in 5-day clonogenic assays in methylcellulose with MCF-12A as untrans-
fected, stably transfected with pPMSKH1, or pPMSKH1-HGFIN siRNA. (b) The total number of colonies in methylcellulose cultures, plated with 100 
cells/dish are presented as mean ± SD, n = 5. (c) Growth curves were established with MCF-12A as untransfected or stably transfected pPMSKH1 
or pPMSKH1-HGFIN siRNA. The total numbers of viable cells were counted at weekly intervals and the results presented as mean ± SD, n = 5. *p 
< 0.05 vs culture with pPMSKH1-HGFIN siRNA.Available online http://breast-cancer-research.com/content/9/5/R58
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it was less effective (Figure 5c, right bars). In summary, on
these results show a role for wild-type p53 in reversing the
suppressive effect of exon 1 in HGFIN activity.
Role of wild-type p53 in HGFIN reporter gene activity
MDA-MB-231 expresses mutant p53 [24]. We therefore
wanted to verify whether our MDA-MB-231 also expressed
functionally mutated p53. This was addressed by transfecting
pLuc into MDA-MB-231 with or without ectopic expression of
p53 and then determined luciferase activity. Cells were co-
transfected with pLuc and/or pME18S-SN3 wild-type p53,
pME18S-SCX3 mutant and pPME18S vector alone. Control
studies used K562 cells stimulated with 10 nM neurokinin-A
that can activate p53 [23]. The result showed significant (p <
0.05) increase in luciferase activity in transfectants with wild-
type p53 as compared to vector alone or mutant p53 (Figure
6a). Control studies for pLuc activities were performed with
K562, based on previous studies that showed its ability to acti-
vate p53 (Figure 6a) [23].
MDA-MB-231 cells were co-transfected with p53 and pGL3-
HGFIN-RM/2.0 or -2.0E. In the case of HGFIN-2.0, p53
expression led to increased luciferase by fourfold as compared
to p53 mutant transfectants (Figure 6b). A similar increase
was not observed for HGFIN-2.0E. This indicates that reduced
HGFIN in the highly aggressive MDA-MB-231 could be partly
explained by wild-type p53.
Figure 3
HGFIN imparts contact-dependent growth by T47D HGFIN imparts contact-dependent growth by T47D. (a) Representative (n = 5) colonies from clonogenic assays with T47D, as untransfected T47D 
(top panel); ectopically expressed for HGFIN (middle panel) or transfected with vector alone (lower panel). (b) T47D, untransfected or stably trans-
fected with pFLAG-HGFIN were studied in clonogenic assays with 100 cells/35 mm2 dishes. At day 5, the total number of colonies were counted 
and are presented as mean ± SD, n = 5. *p < 0.05 vs untransfected and vector transfectants.
Figure 4
Role of HGFIN in cell migration Role of HGFIN in cell migration. MCF12A and MCF10 were knock-out 
for HGFIN, and T47D were ectopically expressed for HGFIN. All cell 
types were studied in cell migration assays. Controls were performed 
with MCF12A and MCF10 as untransfected, vector transfectants or 
transfectants with HGFIN mutant siRNA. Controls for T47D used 
untransfected cells or vector transfectants. All values for the control 
groups were pooled and presented together in single bars. The data 
are presented as mean ± SD, n = 5.Breast Cancer Research    Vol 9 No 5    Metz et al.
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Figure 5
Role of exon 1 in the activity of the 5' flanking region of HGFIN Role of exon 1 in the activity of the 5' flanking region of HGFIN. (a) Car-
toon of the upstream region of HGFIN. TS, transcription start site. (b) 
Non-tumorigenic (MCF12A) and tumorigenic (T47D, HCC70, MDA-
MB-231) breast cells were co-transfected with pGL3-HGFIN-RM/2.0 
or -RM/2.0E and pGal. Luciferase activities were normalized with β-
galactosidase activities and the data are presented as the mean ± SD, 
n = 6. *p < 0.05 vs HGFIN-RM/2.0; **p > 0.05 vs HGFIN-RM/2.0E, 
MDA-MB-231. (c) T47D were co-transfected with HGFIN-RM/2.0 or 
HGFIN-RM/2.0E, and wild-type or mutant p53 expression vectors. 
Controls were transfected with vector alone. Luciferase activities were 
determined 16 h after transfection. The data are presented as mean ± 
SD, n = 6.
Figure 6
HGFIN reporter gene activity in MDA-MB-231, ectopically expressed  for p53 HGFIN reporter gene activity in MDA-MB-231, ectopically expressed 
for p53. (a) MDA-MB-231 was co-transfected with pLuc and/or 
pME18S-SCX3 expression p53, mutant or vector alone. K562 trans-
fected with pLuc served as control. The results are presented as mean 
± SD, n = 5. (b) MDA-MB-231 was co-expressed with HGFIN-RM/2.0 
or HGFIN-RM/2.0E and/or p53 expression vector, pME18S-SCX3. 
Controls were co-transfected with p53 mutants or vector alone. The 
results were normalized with β-galactosidase and are presented as 
mean ± SD, n = 6. *p < 0.05 vs vector/untransfected and mutant p53.Available online http://breast-cancer-research.com/content/9/5/R58
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Discussion
This study expands on previous reports that link HGFIN and
its rodent homolog, osteoactivin, to malignancy. We screened
primary breast tissues and found HGFIN expression in non-
tumorigenic cells, but low to undetectable expression in
malignant cells (Figure 1; Table 1). The fact that HGFIN is reg-
ulated by multiple p53 binding sites, combined with other
studies linking the human gene to low metastatic potential in
melanoma cells suggest that HGFIN might function as a tumor
suppressor [2,12]. Similar to most genes with tumor suppres-
sor activity, HGFIN and osteoactivin have also been linked to
properties consistent with malignancies [4,11,25]. Our labora-
tory has just begun to focus on HGFIN as a tumor-associated
gene, indicating an early investigational stage in studies linked
to this gene. To fully understand a role for HGFIN in breast tis-
sues, research studies beyond those presented are required.
These include quantitative studies to determine if HGFIN lev-
els are linked to the status of the cancer cells. This could be
accomplished in follow-up studies with patients' samples in
longitudinal studies, or with isogenic breast cancer cells. It is
interesting that HGFIN is located on chromosome 7, which is
surrounded by microsatellite regions. Thus, it would be of
interest to examine malignant cells for loss of the HGFIN gene
or loss of heterozygosis.
Exon 1 appears to be critical in the control of HGFIN expres-
sion mainly due to being partly inhibitory in the enhancing func-
tion of its activities (Figure 5a,b). It is interesting that the most
aggressive cell line, MDA-MB-231 cannot activate HGFIN
reporter gene activity unless p53 was expressed, suggesting
that p53 might be the limiting dysfunction in some cancers
with respect to HGFIN expression (Figure 5b,c). In addition to
the multiple p53 sites reported for HGFIN-RM/2.0, a consen-
sus sequence has been found in exon 1 [12]. Ectopic expres-
sion of p53 led to the activation of HGFIN-RM/2.0E (Figure
5c). However, it is unclear if this increase involves exon 1, as
a significant increase was observed for HGFIN-RM/2.0, which
has exon 1 omitted (Figure 5c). Exon 1 could be important in
unraveling the role of HGFIN in malignancies, not only in
breast but also in other cancers. The molecular analysis of
HGFIN is the subject of intense research investigation in our
laboratory.
We have observed an inverse relationship between HGFIN
reporter gene activity and the aggressiveness of breast cancer
cells (Figure 5b) [26]. The reporter gene activities are consist-
ent with decreased HGFIN mRNA in cancer cells, as com-
pared to non-tumorigenic cells (Figure 1). Although we have
shown knock-out of HGFIN causes an increase in cell growth,
contact independent growth and migration (Figures 2, 3, 4), its
role needs to be examined with robust genetic approaches.
Indeed, computer analyses have shown evidence of HGFIN
within a region of microsatellites, which is linked to instability
(data not shown). This observation is currently under investiga-
tion, with pairs of autologous samples to show whether loss of
HGFIN  might be an early event in breast cancer
transformation.
In summary, the HGFIN  (or  nmb) gene and its murine
homolog, osteoactivin are unexplored in cancer biology and in
particular in the capacity of oncogenes. This study has begun
the further examination of this gene at the genetic level. Net-
works comprising HGFIN with cell cycle regulators, estab-
lished oncogenes and tumor suppressors need to be
elucidated. The location of this gene and its control via multiple
p53 sites is intriguing, and might have a critical role in tumor
biology. The functional behavior of HGFIN is reminiscent of
the dual role of p53 as tumor suppressor and as an oncogene
[27,28]. Finally, the hormone status of patients appears to be
irrelevant to the functions of HGFIN, suggesting a global func-
tion of HGFIN (Table 1).
Conclusion
HGFIN exhibits properties that are consistent with tumor sup-
pressor gene functions. In its absence, non-tumorigenic cells
show evidence of transformation and loss of contact depend-
ency as well as increased migration. These findings have been
verified with primary breast tissues in which benign tissues
show expression of HGFIN, whereas malignant tissues shown
no evidence of HGFIN. The relationship between mutated p53
and HGFIN expression in malignancy of breast cancer and
bone invasion will begin to unravel a new pathway used by p53
in breast cancer biology. Also, as this study was performed by
overexpression of one variant of HGFIN, it is unclear how the
extra 12 amino acid insert between exons 1 and 2 in the extra-
cellular domain of the other human variant will affect the biol-
ogy reported in this study [29].
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